Trials / Completed
CompletedNCT00140023
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
A Multi-center, Open Label Study to Evaluate the Efficacy and Safety of Azithromycin Microspheres in Subjects Identified as Having Low Risk Community Acquired Pneumonia (CAP)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will assess the clinical efficacy at Day 14-21 (Test of Cure), 14-21 days after starting the study drug; those subjects from whom a baseline pathogen is identified will also be assessed for bacteriologic response. All subjects who receive 1 dose of study medication will be assessed for safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azithromycin microspheres 2.0 single dose |
Timeline
- Start date
- 2005-09-01
- Completion
- 2006-06-01
- First posted
- 2005-08-31
- Last updated
- 2011-05-10
Locations
5 sites across 1 country: Philippines
Source: ClinicalTrials.gov record NCT00140023. Inclusion in this directory is not an endorsement.